BioCentury
ARTICLE | Deals

Cytokinetics evaluating path forward for heart disease treatment after Amgen ends partnership

November 23, 2020 7:30 PM UTC

Cytokinetics is assessing whether to commercialize omecamtiv mecarbil on its own or to seek a new partner after Amgen returned the heart failure treatment’s rights, ending a 2006 deal.

President and CEO Robert Blum told a conference call Monday that the agreement’s termination came as a surprise to Cytokinetics Inc. (NASDAQ:CYTK), which had intended to discuss its next steps with Amgen Inc. (NASDAQ:AMGN)  next quarter. “We had no indications prior to Friday that Amgen would choose to provide their termination notice” before those next steps took shape, he said...

BCIQ Company Profiles

Amgen Inc.

Cytokinetics Inc.